Antisense Therapeutics (“ANP” or the “Company”) has initiated the process for submission of the ATL1102 for Multiple Sclerosis (MS) Phase IIb IND application with documentation being provided to its Regulatory Agent in the US who, on the Company’s behalf, will submit the IND application to the US Food and Drug Administration (FDA). This submission process is expected to be completed in May. Following the IND submission, the Company must wait 30 calendar days for the FDA review.
Imp...from the announcement above the word EXPECTED to be completed in May....
He never said completed by MAY...my guess is that it's been delayed...We can't be to far away..??? I hope.
Pondering, page-53
-
- There are more pages in this discussion • 25 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
